CS Genetics, a privately held genomics-technology company with headquarters in San Diego, California, and Cambridge, UK, is pioneering a new approach to single-cell genomics. The company has developed an innovative, instrument-free platform designed to revolutionize Next-Generation Sequencing (NGS)-based cellular analysis through its disruptive simplicity, speed, and scalability. At the core of their technology is a unique molecular process called Kinetic Confinement, which fundamentally differs from other single-cell methodologies and seamlessly integrates into existing, widely used laboratory infrastructure. CS Genetics holds an extensive global intellectual property portfolio that encompasses its single-cell platform, along with related reagent, workflow, manufacturing, and application technologies. Their aim is to make high-resolution biological insights accessible at scale, empowering researchers to conduct larger and more complex single-cell studies without the traditional barriers of high cost and complexity.